Eicosanoids in sickle cell disease: Potential relevance of 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid to the pathophysiology of vaso-occlusion

Journal of Laboratory and Clinical Medicine

Volumn 131, Issue 4, 1998, Pages 344-353

  Setty, B N Yamaja ^a   Chen, Dechun ^b   O'Neal, Pat ^b   Littrell, James B ^b   Grossman, Mark H ^b   Stuart, Marie J ^b  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0032055217     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(98)90185-8     Document Type: Article

References (42)

1. Spector AA, Gordon JA, Moore SA. Hydroxyeicosatetraenoicacids (HETEs). Prog Lipid Res 1988;27:271-323.
2. Moore SA, Figard PH, Spector AA, Hart MN. Brain microvessels produce 12-hydroxyeicosatetraenoic acid. J Neurochem 1989;53:376-82.
3. Grossi IM, Fitzgerald LA, Umbarger LA, et al. Bidirectional control of membrane expression and/or activation of the tumor cell IRGpIIb/IIIa receptor and tumor cell adhesion by lipoxygenase products of arachidonic acid and linoleic acid. Cancer Res 1989;49:1029-37.
4. 3 on melanoma cells. Int J Cancer 1991;49:774-86.
5. Tang DG, Chen YQ, Diglio CA, Honn KV. Protein Kinase C-dependent effects of 12(S)-HETE on endothelial cell vitronectin receptor and fibronectin receptor. J Cell Biol 1993;121:689-704.
6. 3 integrins on endothelial cells. Int J Cancer 1993;54:102-11.
7. Sultana C, Shen Y, Rattan V, Kalra VK. Lipoxygenase metabolites induced expression of adhesion molecules and transendothelial migration of monocyte-like HL-60 cells is linked to protein kinase C activation. J Cell Physiol 1996;167:477-87.
8. Setty BNY, Dampier CD, Stuart MJ. Arachidonic acid metabolites are involved in mediating red blood cell adherence to endothelium. J Lab Clin Med 1995;125:608-17.
9. Hebbel RP, Boogaerts MAB, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med 1980;302:992-5.
10. Setty BNY, Phelps DL, Walenga RW, Stuart MJ. Identification of prostaglandins and hydroxyeicosatetraenoic acids in kitten retina: Comparison with other species. Exp Eye Res 1991;53:81-8.
11. Glasser BM, D'Amore PA, Michels RG, Patz A. Demonstrations of vasoproliferative activity from mammalian retina. J Cell Biol 1980;84:298-304.
12. Setty BNY, Stuart MJ. Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood 1996;88:2311-20.
13. Goetzl EJ, Woods JM, Gorman RR. Stimulation of human eosinophil and neutrophil polymorphonuclear leukocyte chemotaxis and random migration by 12-L-hydroxy-5,8,11,14 eicosatetraenoic acid. J Clin Invest 1977;59:179-83.
14. Setty BNY, Graeber JE, Stuart MJ. The mitogenic effect of 15- and 12-hydroxyeicosatetraenoic acid on endothelial cells may be mediated via diacylglycerol kinase inhibition. J Biol Chem 1987;262:17613-22.
15. Tang DG, Renaud C, Stojakovic S, et al. 12(S)-HETE is a mitogenic factor for microvascular endothelial cells: its potential role in angiogenesis. Biochem Biophys Res Commun 1995;211:462-8.
16. Nakao J, Ito H, Koshihara Y, Murota S. Age-related increase in the migration of aortic smooth muscle cells induced by 12-L- hydroxy-5,8,10,14-eicosatetraenoic acid. Atherosclerosis 1984;51:179-87.
17. Setty BNY, Werner MH, Hannun YA, Stuart MJ. 15-Hydroxyeicosatetraenoic acid-mediated potentiation of thrombininduced platelet functions occurs via enhanced production of phosphoinositide-derived second messengers - sn-1,2-diacyl-glycerol and inositol-1,4,5-trisphosphate. Blood 1992;80:2765-73.
18. Sekiya F, Takagi J, Usui T, et al. 12S-Hydroxyeicosatetraenoic acid plays a central role in the regulation of platelet activation. Biochem Biophys Res Comm 1991;179:345-51.
19. Setty BNY, Stuart MJ. 15-Hydroxy-5,8,11,13-eicosatetraenoic acid inhibits human vascular cyclooxygenase: Potential role in diabetic vascular disease. J Clin Invest 1986;77:202-11.
20. Hadjiagapiou C, Spector AA. 12-Hydroxyeicosatetraenoic acid reduces prostacyclin production by endothelial cells. Prostaglandins 1986;31:1135-44.
21. Walenga RW, Sunderji S, Stuart MJ. Formation of hydroxyeicosatetraenoic acids (HETE) in blood from adults versus neonates: reduced production of 12-HETE in cord blood. Pediatr Res 1988;24:563-7.
22. McEver RP. GMP-140: a receptor for neutrophils and monocytes on activated platelets and endothelium. J Cell Biochem 1991;45:156-61.
23. McEver RP. Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. Blood Cells 1990;16:73-83.
24. Hopkins NK, Oglesby TD, Bundy GL, Gorman RR. Biosynthesis and metabolism of 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid by human umbilical vein endothelial cells. J Biol Chem 1984;259:14048-53.
25. Revtyak GE, Hughes MJ, Johnson AR, Campbell WB. Histamine stimulation of prostaglandin and HETE synthesis in human endothelial cells. Am J Physiol 1988;255(Cell Physiol 24):C214-25.
26. Ibe BO, Falck JR, Johnson AR, Campbell WB. Regulation of synthesis of prostacyclin and HETEs in human endothelial cells. Am J Physiol 1989;256(Cell Physiol 25):C1168-75.
27. Lip GYH, Blann AD, Zarifis J, et al. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report. J Hypertension 1995;13:1674-8.
28. Blann AD, Dobrotova M, Kubisz P, McCollum CN. von Willebrand Factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost 1995;74:626-30.
29. Blann AD, Lip GYH. Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis 1997;128:135-8.
30. Jilma B, Eichler H-G,Vondrovec B, et al. Effects of desmopressin on circulating P-selectin. Br J Haematol 1996;93:432-36.
31. Mehta P. Significance of plasma β-thromboglobulin in patients with sickle cell disease. J Pediatr 1980;97:941-4.
32. Adamides S, Konstantopoulos K, Toumbis M, et al. A study of β-thromboglobulin and platelet factor-4 levels in steady state sickle cell patients. Blut 1990;61:245-7.
33. Beurling-Harbury C, Schade SG. Platelet activation during pain crisis in sickle cell anemia patients. Am J Hematol 1989;31:237-41.
34. Haut MJ, Cowan DH, Harris JW. Platelet function and survival in sickle cell disease. J Lab Clin Med 1973;82:44-53.
35. Semple MJ, Al-Hasani SF, Kioy P, Savidge GF. A double-blind trial of ticlopidine in sickle disease. Thromb Haemost 1984;51:303-6.
36. Buchanan GR, Holtkamp CA. Plasma levels of platelet and vascular prostaglandin derivatives in children with sickle cell anaemia. Thromb Haemost 1985;54:394-6.
37. Longenecker GL, Beyers BJ, Mankad VN. Platelet regulatory prostanoids and platelet release products in sickle cell disease. Am J Hematol 1992;40:12-9.
38. Kurantsin-Mills J, Ibe BO, Natta CL, et al. Elevated urinary levels of thromboxane and prostacyclin metabolites in sickle cell disease reflects activated platelets in the circulation. Br J Haematol 1994;87:580-5.
39. 2 agonist U46619. Arterioscler Thromb 1993;13:421-6.
40. Setty BNY, Chen D, Stuart MJ. Sickle cell vaso-occlusive crisis is associated with abnormalities in the ratio of vasoconstrictor to vasodilator prostanoids. Pediatr Res 1995;38:95-102.
41. Wun T, Paglieroni T, Tablin F, et al. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med 1997;129:507-16.
42. 1-Integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium. Blood 1993;82:1891-9.